The history of copyright's flagship drug presents a complex case for observers in the pharmaceutical sector. While initially a phenomenal success, generating vast sums, the intellectual property lapse and the subsequent entry of cheaper alternatives have significantly affected income. This raises questions about the ongoing viability of similar med